Efficacy and Tolerability of Erenumab and Topiramate for Prevention of Chronic Migraine: A Retrospective Cohort Study

• Published in: Medicina
• Main Authors: Eslam El Nebrisi, Zainaba Suaad Ahmed Ruwayya, Dalya Ibrahim Alzayori, Ranya Ibrahim Alzayori, Shyam Babu Chandran, Mohamed Elshafei
• Format: Article
• Language: English
• Published: MDPI AG 2024-10-01
• Subjects: calcitonin gene-related peptide; Erenumab; Topiramate; migraine; prophylaxis; observational
• Online Access: https://www.mdpi.com/1648-9144/60/10/1684
• ISSN: 1010-660X; 1648-9144

<i>Background and Objectives:</i> Migraine is a chronic neurological disorder affecting approximately 14% of the global population. Beyond physical pain, migraines significantly impact individuals’ quality of life, influencing education, employment, and income levels. Topiramate, a second-generation antiepileptic medication, has demonstrated notable efficacy in reducing the occurrence of chronic migraine. Over the past three decades, extensive research has implicated the neuropeptide calcitonin gene-related peptide (CGRP) in migraine pathogenesis. Erenumab, the first FDA-approved CGRP inhibitor, received approval in 2018. This study aims to compare the clinical efficacy of Erenumab and Topiramate for migraine prevention. <i>Materials and Methods:</i> We conducted a retrospective cohort study of adults with episodic or chronic migraine over a 12-month period, comparing Erenumab (<i>n</i> = 52) and Topiramate (<i>n</i> = 56). Outcomes assessed included changes in the Migraine Disability Assessment (MIDAS) scores from baseline over the last three months of treatment and the proportion of patients achieving a ≥50% reduction in MIDAS scores by the end of the study. <i>Results:</i> The Erenumab group showed significant improvement, with nearly 79% of patients achieving a 50% reduction in their MIDAS score, with a mean reduction of 3.76. Notably, only two patients (3.8.5) discontinued treatment due to adverse events. In contrast, the Topiramate group had over 15% of patients achieve a 50% reduction in MIDAS scores, with a mean reduction of 5.89, and a had discontinuation rate of 14.2% due to adverse events. <i>Conclusions:</i> Both Topiramate and Erenumab are effective for migraine prevention. However, Topiramate has lower tolerability and more side effects, while Erenumab offers better tolerability and safety at a higher cost. Treatment decisions should be individualized based on patient needs, efficacy, safety, and cost considerations.